Published in Blood Transfus on April 01, 2009
Von Willebrand Factor in Pregnancy (VIP) Study (VIP) | NCT04146376
Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus (2014) 1.46
Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults. Blood Transfus (2015) 1.46
Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica (2013) 1.19
The demand for factor VIII and for factor IX and the toll fractionation product surplus management. Blood Transfus (2013) 1.05
Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative period. Blood Transfus (2011) 0.95
von Willebrand's disease: a report from a meeting in the Åland islands. Haemophilia (2012) 0.89
Clinical use of factor VIII and factor IX concentrates. Blood Transfus (2013) 0.80
Current therapy in children and adolescents with von Willebrand disease. J Med Life (2014) 0.75
Treatment of patients with von Willebrand disease. J Blood Med (2011) 0.75
Current and Emerging Options for the Management of Inherited von Willebrand Disease. Drugs (2017) 0.75
Efficacy of Octocog Alfa (Advate) in a Child with Type 3 von Willebrand Disease and Alloantibodies. J Clin Med (2017) 0.75
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
Epidemiological investigation of the prevalence of von Willebrand's disease. Blood (1987) 3.24
Treatment of von Willebrand's Disease. N Engl J Med (2004) 3.19
High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med (2000) 2.86
Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost (2002) 1.96
Hemostatic drugs. N Engl J Med (1998) 1.93
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost (2007) 1.69
Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood (1997) 1.57
Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica (2003) 1.56
Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood (2008) 1.30
Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia (2002) 1.21
Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood (2003) 1.17
Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood (2002) 1.12
Venous thromboembolism in von Willebrand disease. Thromb Haemost (2002) 1.11
Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost (2005) 1.06
How I treat patients with von Willebrand disease. Blood (2001) 1.06
von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost (2007) 1.05
Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med (1988) 1.04
Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients. Blood (1991) 1.01
Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia (2003) 0.99
Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost (2002) 0.99
Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P). Haemophilia (2004) 0.97
Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study. Haemophilia (2007) 0.97
Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. Haematologica (2007) 0.97
Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis (2005) 0.95
Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol (1992) 0.95
Hyponatremia and seizures in young children given DDAVP. Am J Hematol (1989) 0.94
The reproductive health of women with von Willebrand Disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost (1995) 0.93
Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis (1996) 0.91
Proceedings: The release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-d-arginine vasopressin, angiotensin and oxytocin in man. Br J Haematol (1974) 0.89
Thrombosis following desmopressin for uremic bleeding. Am J Hematol (1988) 0.89
Type IIB von Willebrand's disease presenting as thrombocytopenia during pregnancy. Br J Haematol (1987) 0.88
Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study. Haemophilia (2002) 0.88
Use of desmopressin (DDAVP) during early pregnancy in factor VIII-deficient women. Blood (2005) 0.87
Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. Eur J Haematol (1987) 0.86
Treatment for patients with type 3 von Willebrand disease and alloantibodies: a case report. Haemophilia (2008) 0.82
Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results. Haemophilia (2007) 0.82
Clinical practice guidelines. The Agency for Health Care Policy and Research fosters the development of evidence-based guidelines. Health Prog (1992) 0.81
Hemostasis in patients with severe von Willebrand disease improves after normal platelet transfusion and normalizes with further correction of the plasma defect. Transfusion (1997) 0.80
Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease. Haemophilia (2008) 0.79
Spontaneous platelet aggregation during pregnancy in a patient with von Willebrand disease type IIB can be blocked by monoclonal antibodies to both platelet glycoproteins Ib and IIb/IIIa. Br J Haematol (1990) 0.76
Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood (2006) 2.36
NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) (2008) 2.23
Adverse reactions in blood and apheresis donors: experience from two Italian transfusion centres. Blood Transfus (2009) 1.62
Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia (2010) 1.59
Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. Blood (2008) 1.57
Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers. J Thromb Haemost (2012) 1.57
Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica (2003) 1.56
How I treat rare venous thromboses. Blood (2008) 1.56
Efficacy of Helicobacter pylori eradication in raising platelet count in adult patients with idiopathic thrombocytopenic purpura. Haematologica (2002) 1.54
Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood (2008) 1.54
Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. Bone (2006) 1.50
Quality and reliability of routine coagulation testing: can we trust that sample? Blood Coagul Fibrinolysis (2006) 1.50
Effects on health of air pollution: a narrative review. Intern Emerg Med (2015) 1.48
The syndrome of the "obsessive-compulsory scientist": a new mental disorder? Clin Chem Lab Med (2013) 1.47
Together we care: new challenges for global haemophilia treatment centers. Indian J Med Res (2009) 1.44
Recombinant human erythropoietin facilitates autologous blood collections in children undergoing corrective spinal surgery. Transfusion (2004) 1.42
Routine coagulation tests in newborn and young infants. J Thromb Thrombolysis (2007) 1.42
A new candidate mutation, G1629R, in a patient with type 2A von Willebrand's disease: basic mechanisms and clinical implications. Haematologica (2004) 1.41
Phlebotomy issues and quality improvement in results of laboratory testing. Clin Lab (2006) 1.41
Simultaneous genotyping of coagulation factor XI type II and type III mutations by multiplex real-time polymerase chain reaction to determine their prevalence in healthy and factor XI-deficient Italians. Haematologica (2008) 1.41
Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms. Blood (2013) 1.39
Mental depression and cardiovascular disease: a multifaceted, bidirectional association. Semin Thromb Hemost (2009) 1.39
The growing impact of publications in haemostasis and thrombosis journals. Thromb Haemost (2007) 1.38
How I treat the acquired von Willebrand syndrome. Blood (2011) 1.36
The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta (2008) 1.33
Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood (2008) 1.30
The role of ethnicity, age and gender in venous thromboembolism. J Thromb Thrombolysis (2010) 1.24
Evaluation and management of postpartum hemorrhage: consensus from an international expert panel. Transfusion (2014) 1.20
Prophylaxis in people with haemophilia. Thromb Haemost (2009) 1.19
Clinical usefulness of measuring red blood cell distribution width on admission in patients with acute coronary syndromes. Clin Chem Lab Med (2009) 1.19
An unusual case of a spurious, transfusion-acquired haemoglobin S. Blood Transfus (2010) 1.16
Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol (2011) 1.15
Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature. Semin Thromb Hemost (2012) 1.15
Haemorrhage and amyloidosis. Br J Haematol (2012) 1.14
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood (2007) 1.13
Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol (2008) 1.12
Increased mean platelet volume in patients with acute coronary syndromes. Arch Pathol Lab Med (2009) 1.11
Doping in competition or doping in sport? Br Med Bull (2008) 1.11
Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis (2003) 1.11
Influence of a light meal on routine haematological tests. Blood Transfus (2010) 1.10
Imatinib and regression of type 2 diabetes. N Engl J Med (2005) 1.09
Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol (2009) 1.08
Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B. Blood (2010) 1.08
Caution during use of desmopressin in IPSS. J Neurointerv Surg (2012) 1.07
The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clin Chem Lab Med (2010) 1.06
Moderate red wine consumption and cardiovascular disease risk: beyond the "French paradox". Semin Thromb Hemost (2010) 1.05
A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance. Eur J Haematol Suppl (2008) 1.04
Biochemistry, physiology, and complications of blood doping: facts and speculation. Crit Rev Clin Lab Sci (2006) 1.03
How to write a scientific manuscript for publication. Blood Transfus (2012) 1.02
Ribosome readthrough accounts for secreted full-length factor IX in hemophilia B patients with nonsense mutations. Hum Mutat (2012) 1.01
Help me, Doctor! My D-dimer is raised. Ann Med (2008) 1.01
Mesenchymal stem cells: from biology to clinical use. Blood Transfus (2007) 1.00
Thrombotic complications of erythropoiesis-stimulating agents. Semin Thromb Hemost (2010) 1.00
Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost (2013) 0.99
Influenza and cardiovascular disease: does swine-origin, 2009 H1N1 flu virus represent a risk factor, an acute trigger, or both? Semin Thromb Hemost (2010) 0.99
An intact PDZ motif is essential for correct P2Y12 purinoceptor traffic in human platelets. Blood (2011) 0.99
Identification of spurious hemolysis in anticoagulated blood with Sysmex XE-2100 and Siemens Advia 2120. Clin Lab (2012) 0.98
Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. Haematologica (2007) 0.97
Platelet gel in the treatment of cutaneous ulcers: the experience of the Immunohaematology and Transfusion Centre of Parma. Blood Transfus (2010) 0.96
Stability of blood cell counts, hematologic parameters and reticulocytes indexes on the Advia A120 hematologic analyzer. J Lab Clin Med (2005) 0.96
Determinants of anaemia in the very elderly: a major contribution from impaired renal function? Blood Transfus (2010) 0.96
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood (2013) 0.96
Diagnosis and management of ischemic heart disease. Semin Thromb Hemost (2013) 0.94
Old and new anticoagulant drugs: a minireview. Ann Med (2011) 0.94
Inherited and acquired factor V deficiency. Blood Coagul Fibrinolysis (2011) 0.94
Long-term persistence of molecular response after discontinuation of interferon-alpha in two patients with chronic myeloid leukaemia. Blood Transfus (2011) 0.94
Hemostasis, cancer, and ABO blood group: the most recent evidence of association. J Thromb Thrombolysis (2014) 0.94
An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees. Blood (2004) 0.93
Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future. J Thromb Thrombolysis (2010) 0.93
Shortened activated partial thromboplastin time: causes and management. Blood Coagul Fibrinolysis (2010) 0.93
VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood (2013) 0.93
The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor. Thromb Haemost (2002) 0.92
TCF2 gene mutation leads to nephro-urological defects of unequal severity: an open question. Med Sci Monit (2008) 0.92
Frequency and type of newly diagnosed haemoglobin variants in Northern Italy. Blood Transfus (2010) 0.92
Thromboembolism in childhood nephrotic syndrome: a rare but serious complication. Hematology (2007) 0.92
Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol (2011) 0.91
Non-O blood group: an important genetic risk factor for venous thromboembolism. Blood Transfus (2012) 0.91
The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica (2008) 0.91
Effectiveness of low-dose oral calcium carbonate for the prevention of citrate-related toxicity in peripheral blood stem cell collection. Blood Transfus (2011) 0.91
Expression of CD27 and CD23 on peripheral blood B lymphocytes in humans of different ages. Blood Transfus (2009) 0.91
Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. Semin Thromb Hemost (2012) 0.90
Acquired haemophilia A as a blood transfusion emergency. Blood Transfus (2008) 0.90
Molecular diversity and thrombotic risk in protein S deficiency: the PROSIT study. Hum Mutat (2005) 0.90
Comparison of serum creatinine, uric acid, albumin and glucose in male professional endurance athletes compared with healthy controls. Clin Chem Lab Med (2004) 0.90
Intensive blood transfusion support in acquired hemophilia A. Ann Hematol (2006) 0.90
Genetic and biochemical heterogeneity of cardiac troponins: clinical and laboratory implications. Clin Chem Lab Med (2009) 0.89
Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Semin Thromb Hemost (2012) 0.89
Classic thrombophilic gene variants. Thromb Haemost (2015) 0.89
Lipoprotein[a] and cancer: anti-neoplastic effect besides its cardiovascular potency. Cancer Treat Rev (2007) 0.89
Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost (2011) 0.88
How I treat von Willebrand disease. Blood (2009) 0.88
Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis. Diabetes Care (2007) 0.88